Tilray Expands Medical Cannabis Portfolio in Germany
Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), has announced an expansion of its medical cannabis extract portfolio in Germany. The company introduced two new product offerings:
1. Tilray THC50 CBD50 (25ml): A high-potency 1:1 medical cannabis extract designed for patients requiring higher cannabinoid content
2. Tilray THC10 CBD10 (10ml): A new trial size version of their top-selling medical cannabis extract, created to allow more accessible initial dosing and treatment exploration
The expansion responds to increasing demand for balanced medical cannabis extracts in Germany, where Tilray maintains its position as the leading provider of medical cannabis extracts. The products are available with a physician's prescription at pharmacies throughout Germany.
Tilray Medical, una divisione di Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), ha annunciato un'espansione del suo portafoglio di estratti di cannabis medicinale in Germania. L'azienda ha introdotto due nuove offerte di prodotto:
1. Tilray THC50 CBD50 (25ml): Un estratto di cannabis medicinale ad alta potenza 1:1, progettato per pazienti che necessitano di un contenuto più elevato di cannabinoidi.
2. Tilray THC10 CBD10 (10ml): Una nuova versione di prova del loro estratto di cannabis medicinale più venduto, creata per consentire un dosaggio iniziale e un'esplorazione del trattamento più accessibili.
L'espansione risponde a una domanda crescente di estratti di cannabis medicinale bilanciati in Germania, dove Tilray mantiene la sua posizione di principale fornitore di estratti di cannabis medicinale. I prodotti sono disponibili con prescrizione medica in farmacie in tutta la Germania.
Tilray Medical, una división de Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), ha anunciado una expansión de su cartera de extractos de cannabis medicinal en Alemania. La compañía presentó dos nuevos productos:
1. Tilray THC50 CBD50 (25ml): Un extracto de cannabis medicinal de alta potencia en proporción 1:1, diseñado para pacientes que requieren un mayor contenido de cannabinoides.
2. Tilray THC10 CBD10 (10ml): Una nueva versión de tamaño de prueba de su extracto de cannabis medicinal más vendido, creada para permitir un inicio de tratamiento y dosificación más accesibles.
La expansión responde a la creciente demanda de extractos de cannabis medicinal equilibrados en Alemania, donde Tilray se mantiene como el principal proveedor de extractos de cannabis medicinal. Los productos están disponibles con receta médica en farmacias de toda Alemania.
틸레이 메디컬, 틸레이 브랜드 주식회사 (NASDAQ: TLRY; TSX: TLRY)의 분과, 독일에서 의약용 대마 추출물 포트폴리오의 확장을 발표했습니다. 회사는 두 가지 새로운 제품을 소개했습니다:
1. 틸레이 THC50 CBD50 (25ml): 더 높은 칸나비노이드 함량이 필요한 환자를 위해 설계된 고농도 1:1 의약용 대마 추출물입니다.
2. 틸레이 THC10 CBD10 (10ml): 초기 투여와 치료 탐색을 더 접근 가능하게 하기 위해 만든 베스트셀러 의약용 대마 추출물의 새로운 시험 크기 버전입니다.
이 확장은 독일에서 균형 잡힌 의약용 대마 추출물에 대한 수요 증가에 대응하여 이루어졌으며, 틸레이는 의약용 대마 추출물의 주요 공급자로 자리 잡고 있습니다. 이 제품은 독일 전역의 약국에서 의사의 처방으로 이용할 수 있습니다.
Tilray Medical, une division de Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), a annoncé l'élargissement de son portefeuille d'extraits de cannabis médical en Allemagne. L'entreprise a introduit deux nouveaux produits :
1. Tilray THC50 CBD50 (25ml): Un extrait de cannabis médical à forte puissance en proportion 1:1, conçu pour les patients ayant besoin d'un plus fort contenu en cannabinoïdes.
2. Tilray THC10 CBD10 (10ml): Une nouvelle version en format d'essai de leur extrait de cannabis médical le plus vendu, créée pour permettre une posologie initiale et une exploration du traitement plus accessibles.
L'expansion répond à la demande croissante d'extraits de cannabis médical équilibrés en Allemagne, où Tilray reste le principal fournisseur d'extraits de cannabis médical. Les produits sont disponibles avec une prescription médicale dans les pharmacies à travers l'Allemagne.
Tilray Medical, eine Abteilung von Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), hat eine Erweiterung seines Portfolios an medizinischen Cannabisextrakten in Deutschland angekündigt. Das Unternehmen stellte zwei neue Produkte vor:
1. Tilray THC50 CBD50 (25ml): Ein hochwirksamer 1:1 medizinischer Cannabisextrakt, der für Patienten entwickelt wurde, die einen höheren Cannabinoidgehalt benötigt.
2. Tilray THC10 CBD10 (10ml): Eine neue Testgrößen-Version ihres meistverkauften medizinischen Cannabisextraktes, die es ermöglicht, eine zugänglichere Anfangsdosierung und Behandlungserkundung zu bieten.
Die Expansion reagiert auf die steigende Nachfrage nach ausgewogenen medizinischen Cannabisextrakten in Deutschland, wo Tilray seine Position als führender Anbieter von medizinischen Cannabisextrakten beibehält. Die Produkte sind in Apotheken in ganz Deutschland mit einem Rezept erhältlich.
- Expansion of product portfolio in key German market
- Market leadership position in German medical cannabis extracts
- Introduction of new high-potency formulation meeting higher dosage needs
- Launch of smaller trial size format improving accessibility
- None.
Insights
This portfolio expansion in Germany marks a significant strategic development for Tilray, demonstrating sophisticated product differentiation in Europe's largest medical cannabis market, valued at approximately
The timing is particularly strategic as Germany moves toward broader cannabis reform, positioning Tilray to capitalize on potential regulatory changes. The company's focus on balanced THC:CBD formulations aligns with German physician prescribing preferences and established medical protocols, potentially driving increased adoption rates.
From a market perspective, this expansion reinforces Tilray's first-mover advantage in German medical cannabis extracts. The introduction of varying sizes and potencies creates multiple price points and treatment options, potentially expanding the addressable patient base. The smaller trial size format could accelerate patient acquisition by lowering initial prescription costs, while the higher potency option may improve patient retention and lifetime value.
Critical to note is how this portfolio expansion strengthens Tilray's competitive moat in Germany through:
- Enhanced product differentiation in a market where standardization is crucial
- Improved pharmacy relationships through broader product offerings
- Strengthened physician engagement through more flexible prescribing options
- Increased barriers to entry for competitors due to expanded market coverage
Global Leader in Medical Cannabis Launches New Cannabis Extract Products and Formulations
NEUMÜNSTER, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, is pleased to announce the expansion of its industry-leading medical cannabis extract portfolio in Germany. Tilray’s new medical cannabis offerings in Germany includes the introduction of an additional product size for its top-selling medical cannabis extract, along with a new formulation aimed at addressing the diverse needs of patients and healthcare providers. Recognizing the increasing demand for balanced medical cannabis extracts, which are among the top-prescribed medical cannabis extracts in Germany, Tilray Medical introduces the following:
Tilray THC50 CBD50 (25ml): A high-potency 1:1 medical cannabis extract designed for patients requiring higher cannabinoid content, offering an option for those who need stronger therapeutic effects while maintaining the same balanced THC:CBD ratio that has become in demand in Germany.
Tilray THC10 CBD10 (10ml): A new trial size version of Tilray Medical’s top selling medical cannabis extract, responding to patients and physicians demand for smaller formats that allow for more accessible initial dosing and treatment exploration.
Denise Faltischek, Chief Strategy Officer and Head of International, said, "Our unwavering focus on innovation and education, together with our dedication to patient care drives everything we do. Because of this, physicians and patients around the world trust the efficacy and safety of our products, which is evidenced by our position as the leading provider of medical cannabis extracts in Germany. In consultation with healthcare providers, we continuously evaluate our portfolio and are developing new innovations, including these new product launches to meet diverse patient needs. "
Tilray Medical's medical cannabis products are available with a physician's prescription at pharmacies throughout Germany.
- Tilray THC10 CBD10 25ml & 10ml
- Tilray THC50 CBD50 25ml
- Tilray THC25 CBD25 25ml
- Tilray THC25
- Tilray THC5 CBD20
- Tilray THC20 CBD6
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Broken Coast, Redecan, Good Supply and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Portugal and Germany. Today, Tilray Medical is a leading supplier of medical cannabis with a portfolio of brands and products designed to meet the needs of our patients worldwide.
For further information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, New Zealand and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For further information:
Media: news@tilray.com
Investor Relations: investors@tilray.com
FAQ
What new medical cannabis products did Tilray (TLRY) launch in Germany in February 2025?
Where are Tilray's (TLRY) medical cannabis products available in Germany?
What is Tilray's (TLRY) market position in German medical cannabis extracts?
Why did Tilray (TLRY) introduce a 10ml trial size product in Germany?
What is the THC:CBD ratio in Tilray's (TLRY) new high-potency extract?
